213 related articles for article (PubMed ID: 23603367)
61. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
62. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
63. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women.
Lee SY; Kim MK; Park H; Yoon BS; Seong SJ; Kang JH; Jun HS; Park CT
J Gynecol Oncol; 2010 Jun; 21(2):102-5. PubMed ID: 20613900
[TBL] [Abstract][Full Text] [Related]
64. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
65. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
67. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
Amezcua CA; Zheng W; Muderspach LI; Felix JC
Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Lv X; Guo L; Wang C
J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
[TBL] [Abstract][Full Text] [Related]
69. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
Jiang J; Du H; Peng H
Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
[TBL] [Abstract][Full Text] [Related]
70. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium.
Salmi A; Pakarinen P; Peltola AM; Rutanen EM
Mol Hum Reprod; 1998 Dec; 4(12):1110-5. PubMed ID: 9872360
[TBL] [Abstract][Full Text] [Related]
71. Long-term use of the levonorgestrel-releasing intrauterine system.
Inki P
Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611
[TBL] [Abstract][Full Text] [Related]
72. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system.
Möller B; Rönnerdag M; Wang G; Odlind V; Olovsson M
Hum Reprod; 2005 May; 20(5):1410-7. PubMed ID: 15760960
[TBL] [Abstract][Full Text] [Related]
73. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
74. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
Wildemeersch D; Pylyser K; De Wever N; Pauwels P; Tjalma W
Maturitas; 2007 Jun; 57(2):205-9. PubMed ID: 17227699
[TBL] [Abstract][Full Text] [Related]
75. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy.
Inki P; Hurskainen R; Palo P; Ekholm E; Grenman S; Kivelä A; Kujansuu E; Teperi J; Yliskoski M; Paavonen J
Ultrasound Obstet Gynecol; 2002 Oct; 20(4):381-5. PubMed ID: 12383322
[TBL] [Abstract][Full Text] [Related]
76. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
[TBL] [Abstract][Full Text] [Related]
77. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion.
Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G
J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144
[TBL] [Abstract][Full Text] [Related]
78. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
79. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study.
Heikinheimo O; Vani S; Carpén O; Tapper A; Härkki P; Rutanen EM; Critchley H
Hum Reprod; 2007 Sep; 22(9):2515-22. PubMed ID: 17636280
[TBL] [Abstract][Full Text] [Related]
80. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
